AXNX News and Press, Axonics Modulation Technologies Inc. From 08/18/22

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that senior management is scheduled to present at the following investor conferences: Event: We...

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that in the last twelve months, the United States Patent and Trademark Office has granted eight pat...

Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. In the second quarter, the Baron Discovery Fund was down 22.66% (Institutional Shares), which was 3.41% below the Russell...

Axonics, Inc. (Nasdaq: AXNX) (“Axonics”), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the closing of its public offering of 2,012,500 shares of its common stoc...

Axonics ( NASDAQ: AXNX ) priced its earlier announced underwritten public offering of 1.75M shares. Underwriters granted 30-day option to purchase up to 262.5K additional shares. Offer is expected to close on Aug.5, 2022. Net proceeds to be used working capita...

Axonics ( NASDAQ: AXNX ) stock dropped over 3% during extended trading on Tuesday after the medical technology company launched a proposed underwritten public offering of 1.75M shares of its common stock. Terms of the offering are yet to be determined. Axonics ( ...

Axonics, Inc. (AXNX) Q2 2022 Earnings Conference Call August 01, 2022 04:30 PM ET Company Participants Neil Bhalodkar - Investor Relations Raymond Cohen - Chief Executive Officer Dan Dearen - President & Chief Financial Officer Conference Call Participa...

Axonics Modulation Technologies press release ( NASDAQ: AXNX ): Q2 GAAP EPS of -$0.47 beats by $0.07 . Revenue of $69M (+50.3% Y/Y) beats by $8.95M . Axonics has updated its fiscal year 2022 revenue guidance as follows: Total company revenue of ...

Generated record quarterly revenue of $69 million in 2Q22, an increase of 50% compared to 2Q21 Fiscal year 2022 revenue guidance increased to $253 million, an increase of 40% compared to fiscal year 2021 Axonics, Inc. (Nasdaq: AXNX), a global medical technolo...

ShockWave’s disruptive approach within the calcified cardiovascular disease space creates a first-mover advantage offering the opportunity of robust sales growth. ShockWave Medical’s business model looks to “Grow Markets and Take Market Share” targeting an ...